Preparation and evaluation of vitamin A nanosuspension as a novel ocular drug delivery

Document Type: Research Paper

Authors

Nanotechnology Research Center and School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

10.7508/nmj.2015.04.006

Abstract

Objective(s): 
The aim of this study was to prepare a nanosuspension formulation as a new vehicle for the improvement of the ocular delivery of vitamin A. 
Material and Methods:  
Formulations were designed based on full factorial design. A high pressure homogenization technique was used to produce nanosuspensions. Fifteen formulations were prepared by the use of different combinations of surfactants Tween 80, benzalkonium chloride and Pluronic and evaluated for pH, particle size, entrapment efficiency, differential scanning calorimetry (DSC), stability and drug release.  Also, Draize test was used to evaluate the irritation of rabbit eye by formulations. 
Results:  
All formulations showed a small mean size that is well suited for ocular application. Also it was observed that the particle size decreased with increase in the amount of surfactant. Drug entrapment increased with increasing amount of surfactant. It was shown that initial and final drug release can be controlled by the ratio and the total amount of surfactants, respectively.  
Conclusion:  
It was concluded that the use of Tween 80 and Pluronic in the formualtions with a proper ratio does not show eye irritation and could be useful to achieve a suitable nanosuspension of vitamin A as a novel ocular delivery system.

Keywords


1. Chiou GC, Watanabe K. Drug delivery to the eye. Pharmacol Therapeut. 1982; 17(2): 269-278.

2. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliver Rev. 2005; 57(11): 1595-1639.

3. Loftsson T, Stefansson E. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm. 1997; 23(5): 473-481.

4. Loftsson T. Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stability. 1995; 1: 22-33.

5. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008; 13(3): 135-143.

6. Loveday SM, Singh H. Recent advances in technologies for vitamin A protection in foods. Trends Food Sci Tech. 2008; 19(12): 657-668.

7. Robin JS, Ellis PP. Ophthalmic ointments. Surv Ophthalmol. 1978; 22(5): 335-340.

8. Kobayashi T, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica. 1997; 211(6): 358-361.

9. Wright P. Topical retinoic acid therapy for disorders of the outer eye. Trans Ophthalmol Soc UK. 1985; 104: 869-874.

10. Odaka A, Toshida H, Ohta T, Tabuchi N, Koike D, Suto C, Murakami A. Efficacy of retinol palmitate eye drops for dry eye in rabbits with lacrimal gland resection. Clin Ophthalmol. 2012; 6: 1585-1593.

11. Fujikawa A, Gong H, Amemiya T. Vitamin E prevents changes in the cornea and conjunctiva due to vitamin A deficiency. Graef Arch Clin Exp. 2003; 241(4): 287-297.

12. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, GeerlingG. An optimised protocol for the production of autologous serum eyedrops. Graef Arch Clin Exp. 2005; 243(7): 706-714.

13. Glover JC, Renaud JS, Rijli FM. Retinoic acid and hindbrain patterning. J Neurobiol. 2006; 66(7): 705-725.

14. Soong HK, Martin NF, Wagoner MD, Alfonso E, Mandelbaum SH, Laibson PR, Smith RE, Udell I. Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. Ophthalmology. 1988; 95(10): 1442-1446.

15. Ohashi Y, Watanabe H, Kinoshita S, Hosotani H, Umemoto M, Manabe R. Vitamin A eyedrops for superior limbic keratoconjunctivitis. Am J Ophthalmol. 1988; 105(5): 523-527.

16. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010; 12(3): 348-360.

17. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013; 2(2): 47-64.

18. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliver Rev. 1995; 16(1): 39-43.

19. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004; 3(9): 785-796.

20. Bisrat M, Nyström C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm. 1988; 47(1): 223-231.

21. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004; 113(1): 151-170.

22. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract", Eur J Pharm Biopharm. 1997; 44(1): 25-31.

23. Kassem M, Abdel Rahman A, Ghorab M, Ahmed M, Khalil R. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007; 340(1): 126-133.

24. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002; 16(1): 53-61.

25. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine. 2011; 7(2): 242-247.

26. Shokri J, Azarmi S, Sabouri A, Shokri M. Enhancement of oxazepam dissolution rate using oxazepam-surfactant solid dispersions. Pharm Sci. 2006; 4(35): 43-51.

27. Hua XY, Rosen MJ. Dynamic surface tension of aqueous surfactant solutions: I. Basic paremeters. J Colloid Interf Sci. 1988; 124(2): 652-659.

28. Dandagi P, Kerur S, Mastiholimath V, Gadad A, Kulkarni A. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iran J Pharm Res. 2009; 8(2): 79-86.

29. Mishra M, Muthuprasanna P, Prabha KS, Rani PS, Babu S, Chandiran IS, Arunachalam G, Shalini S. Basics and potential applications of surfactants-a review. Int J PharmTech Res. 2009; 1(4): 1354-1365.